Dashboard
Manage Tickers

KALVKalVista Pharmaceuticals, Inc.

Nasdaq kalvista.com


$ 12.48 $ -0.07 (-0.56 %)    

Thursday, 11-Jul-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 492.14 $ -11.03 (-2.19 %)
DIA $ 397.90 $ 0.37 (0.09 %)
SPY $ 556.42 $ -4.84 (-0.86 %)
TLT $ 93.53 $ 0.90 (0.97 %)
GLD $ 223.19 $ 3.89 (1.77 %)
$ 12.5
$ 12.60
$ 0.00 x 0
$ 0.00 x 0
$ 12.05 - $ 12.65
$ 7.21 - $ 16.88
355,146
na
459.83M
$ 1.02
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-11-2024 04-30-2024 10-K
2 03-11-2024 01-31-2024 10-Q
3 12-07-2023 10-31-2023 10-Q
4 09-07-2023 07-31-2023 10-Q
5 07-07-2023 04-30-2023 10-K
6 03-09-2023 01-31-2023 10-Q
7 12-08-2022 10-31-2022 10-Q
8 09-08-2022 07-31-2022 10-Q
9 07-07-2022 04-30-2022 10-K
10 03-10-2022 01-31-2022 10-Q
11 12-09-2021 10-31-2021 10-Q
12 09-09-2021 07-31-2021 10-Q
13 07-13-2021 04-30-2021 10-K
14 03-11-2021 01-31-2021 10-Q
15 12-10-2020 10-31-2020 10-Q
16 09-14-2020 07-31-2020 10-Q
17 07-01-2020 04-30-2020 10-K
18 03-10-2020 01-31-2020 10-Q
19 12-03-2019 10-31-2019 10-Q
20 09-09-2019 07-31-2019 10-Q
21 07-16-2019 04-30-2019 10-K
22 03-14-2019 01-31-2019 10-Q
23 12-14-2018 10-31-2018 10-Q
24 09-14-2018 07-31-2018 10-Q
25 07-30-2018 04-30-2018 10-K
26 03-16-2018 01-31-2018 10-Q
27 12-14-2017 10-31-2017 10-Q
28 09-14-2017 07-31-2017 10-Q
29 07-27-2017 04-30-2017 10-K
30 03-16-2017 01-31-2017 10-Q
31 11-08-2016 09-30-2016 10-Q
32 08-12-2016 06-30-2016 10-Q
33 05-12-2016 03-31-2016 10-Q
34 03-30-2016 12-31-2015 10-K
35 11-12-2015 09-30-2015 10-Q
36 08-13-2015 06-30-2015 10-Q
37 05-21-2015 03-31-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

kalvista-submits-fda-application-for-sebetralstat-phase-3-trial-results-published
KalVista Submits FDA Application for Sebet...
07/11/2024 10:37:03

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and released financial results for the fisca...

kalvista-pharma-q4-eps-102-misses-073-estimate-cash-balance-of-2104m
KalVista Pharma Q4 EPS $(1.02) Misses $(0....
07/11/2024 10:35:02

kalvista-pharmaceuticals-has-initiated-open-label-konfident-kid-trial-of-sebetralstat-in-pediatric-patients-with-hereditary-angioedema-the-trial-will-enroll-approximately-24-children-aged-2-to-11-years
KalVista Pharmaceuticals Has Initiated Ope...
06/27/2024 10:37:39

If approved, sebetralstat would be the first oral on-demand therapy in pediatric patients aged 2 – 11 years, and only the secon...

needham-reiterates-buy-on-kalvista-pharma-maintains-35-price-target
Needham Reiterates Buy on KalVista Pharma,...
06/18/2024 14:45:59

Needham analyst Serge Belanger reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $35 price target.

kalvista-submits-new-drug-application-for-fda-review-of-sebetralstat
KalVista Submits New Drug Application For ...
06/18/2024 10:32:18

Sebetralstat is a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (...

kalvista-pharmaceuticals-presented-us-subgroup-analysis-from-sebetralstat-phase-3-konfident-trial-real-world-claims-and-patient-survey-data-at-eastern-allergy-conference-2024-and-japanese-subgroup-at-annual-meeting-of-japanese-dermatological-association
KalVista Pharmaceuticals Presented US Subg...
06/06/2024 10:35:57

kalvista-highlights-real-world-data-on-hae-treatments-and-patient-experiences-at-eaaci-congress
KalVista Highlights Real-World Data on HAE...
06/03/2024 10:36:32

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that it presented real-world data from US patient surveys that as...

kalvista-pharmaceuticals-presents-late-breaking-phase-3-konfident-trial-data-on-sebetralstat-at-eaaci-congress-nejm-publication-highlights-9-minute-median-time-to-treatment-and-13-hour-symptom-relief-for-laryngeal-attacks-in-konfident-s-trial
KalVista Pharmaceuticals Presents Late-Bre...
05/31/2024 16:17:25

kalvista-pharmaceuticals-says-that-ten-abstracts-accepted-for-presentation-at-the-european-academy-of-allergy-and-clinical-immunology-congress-2024
KalVista Pharmaceuticals Says That Ten Abs...
05/24/2024 10:32:32

The European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024 is taking place in Valencia, Spain from May 31-Ju...

hc-wainwright--co-maintains-buy-on-kalvista-pharma-lowers-price-target-to-20
HC Wainwright & Co. Maintains Buy on KalVi...
05/03/2024 19:44:50

HC Wainwright & Co. analyst Andrew Fein maintains KalVista Pharma (NASDAQ:KALV) with a Buy and lowers the price target f...

needham-reiterates-buy-on-kalvista-pharma-maintains-35-price-target
Needham Reiterates Buy on KalVista Pharma,...
05/01/2024 16:14:49

Needham analyst Serge Belanger reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $35 price target.

kalvista-pharmaceuticals-announced-its-strategic-plans-for-fiscal-year-2025-beginning-may-1-including-for-sebetralstat-the-companys-investigational-novel-oral-plasma-kallikrein-inhibitor-for-the-on-demand-treatment-of-hereditary-angioedema
Kalvista Pharmaceuticals Announced Its Str...
05/01/2024 10:38:07

needham-reiterates-buy-on-kalvista-pharma-maintains-35-price-target
Needham Reiterates Buy on KalVista Pharma,...
04/11/2024 10:07:50

Needham analyst Serge Belanger reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $35 price target.

kalvista-pharmaceuticals-presented-multiple-analyses-of-the-relationship-between-the-time-to-attack-treatment-and-the-effects-delays-in-treatment-have-on-clinical-outcomes-of-hereditary-angioedema-at-the-2024-haei-regional-conference-americas
KalVista Pharmaceuticals Presented Multipl...
03/18/2024 10:46:21

hc-wainwright--co-reiterates-buy-on-kalvista-pharma-maintains-24-price-target
HC Wainwright & Co. Reiterates Buy on KalV...
03/12/2024 10:56:25

HC Wainwright & Co. analyst Andrew Fein reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $24 price target.

kalvista-pharmaceuticals-announced-the-uk-medicines-and-healthcare-products-regulatory-agency-has-awarded-the-promising-innovative-medicine-designation-for-sebetralstat-for-on-demand-treatment-of-hereditary-angioedema
KalVista Pharmaceuticals Announced The UK ...
03/12/2024 10:38:04

needham-maintains-buy-on-kalvista-pharma-maintains-35-price-target
Needham Maintains Buy on KalVista Pharma, ...
03/11/2024 19:52:58

Needham analyst Serge Belanger maintains KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $35 price target.

recap-kalvista-pharma-q3-earnings
Recap: KalVista Pharma Q3 Earnings
03/11/2024 13:30:06

kalvista-pharma-q3-eps-084-misses-077-estimate
KalVista Pharma Q3 EPS $(0.84) Misses $(0....
03/11/2024 10:42:25

KalVista Pharma (NASDAQ:KALV) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0...

kalvista-pharmaceuticals-says-it-will-present-hae-attack-journey-data-at-2024-haei-regional-conference-americas
KalVista Pharmaceuticals Says It Will Pres...
03/08/2024 11:44:20

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)
07/23/2024 Fastly, Inc. (FSLY)
07/29/2024 Enphase Energy, Inc. (ENPH)
07/30/2024 Rivian Automotive, Inc. (RIVN)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)